Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q9JI57

Entry ID Method Resolution Chain Position Source
AF-Q9JI57-F1 Predicted AlphaFoldDB

59 variants for Q9JI57

Variant ID(s) Position Change Description Diseaes Association Provenance
rs3388795802 6 K>E No EVA
rs3388788194 83 D>N No EVA
rs3388798491 94 N>S No EVA
rs3388798679 122 C>* No EVA
rs3388788132 129 Q>K No EVA
rs3388778849 210 D>E No EVA
rs3388798184 236 A>G No EVA
rs3388798122 236 A>T No EVA
rs3388798666 250 P>L No EVA
rs3388804442 274 V>M No EVA
rs3388800834 283 D>H No EVA
rs3388791822 294 H>Y No EVA
rs3388778847 307 Q>* No EVA
rs3388786394 318 Q>K No EVA
rs3388788168 329 S>P No EVA
rs3388793126 357 I>F No EVA
rs3388798635 385 E>* No EVA
rs3388804360 428 D>VSDG* No EVA
rs3388796532 440 D>Y No EVA
rs3388788115 445 E>D No EVA
rs3388798200 446 P>S No EVA
rs3388800892 467 G>V No EVA
rs3388796881 469 A>V No EVA
rs3388804389 478 E>D No EVA
rs3388790624 498 P>VSDG* No EVA
rs3388793163 502 D>G No EVA
rs3388786405 552 R>W No EVA
rs3388782557 604 L>V No EVA
rs3388796512 618 F>S No EVA
rs3388791759 624 R>E* No EVA
rs3388786260 625 K>R No EVA
rs3388795880 628 E>G No EVA
rs3396202162 705 A>P No EVA
rs3396087862 709 K>* No EVA
rs3396002787 709 K>R No EVA
rs3396002792 710 Y>C No EVA
rs3388790662 712 V>A No EVA
rs3388790662 712 V>E No EVA
rs3388800841 712 V>L No EVA
rs3388800816 720 K>Q No EVA
rs3388796911 741 C>Y No EVA
rs3388788189 743 F>L No EVA
rs3388791755 754 V>M No EVA
rs3388796870 757 K>R No EVA
rs3388796476 805 A>T No EVA
rs3388796497 809 G>W No EVA
rs3388784595 824 E>D No EVA
rs3388782576 824 E>K No EVA
rs3388768445 839 P>L No EVA
rs3388795811 878 A>D No EVA
rs3388796502 920 Q>E No EVA
rs3388768438 922 K>SDG* No EVA
rs3388782505 924 L>F No EVA
rs3388778907 973 H>Q No EVA
rs3388796536 998 D>N No EVA
rs3388765667 1013 K>M No EVA
rs3388790646 1082 H>P No EVA
rs3388765632 1083 W>R No EVA
rs3388804354 1086 R>K No EVA

No associated diseases with Q9JI57

6 regional properties for Q9JI57

Type Name Position InterPro Accession
repeat GTF2I-like repeat 119 - 213 IPR004212-1
repeat GTF2I-like repeat 342 - 436 IPR004212-2
repeat GTF2I-like repeat 556 - 650 IPR004212-3
repeat GTF2I-like repeat 681 - 775 IPR004212-4
repeat GTF2I-like repeat 805 - 899 IPR004212-5
repeat GTF2I-like repeat 908 - 1002 IPR004212-6

Functions

Description
EC Number
Subcellular Localization
  • Nucleus
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

3 GO annotations of cellular component

Name Definition
cytosol The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
nucleoplasm That part of the nuclear content other than the chromosomes or the nucleolus.
nucleus A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.

3 GO annotations of molecular function

Name Definition
DNA-binding transcription factor activity A transcription regulator activity that modulates transcription of gene sets via selective and non-covalent binding to a specific double-stranded genomic DNA sequence (sometimes referred to as a motif) within a cis-regulatory region. Regulatory regions include promoters (proximal and distal) and enhancers. Genes are transcriptional units, and include bacterial operons.
DNA-binding transcription repressor activity, RNA polymerase II-specific A DNA-binding transcription factor activity that represses or decreases the transcription of specific gene sets transcribed by RNA polymerase II.
RNA polymerase II cis-regulatory region sequence-specific DNA binding Binding to a specific upstream regulatory DNA sequence (transcription factor recognition sequence or binding site) located in cis relative to the transcription start site (i.e., on the same strand of DNA) of a gene transcribed by RNA polymerase II.

3 GO annotations of biological process

Name Definition
negative regulation of transcription by RNA polymerase II Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase II.
transcription by RNA polymerase II The synthesis of RNA from a DNA template by RNA polymerase II (RNAP II), originating at an RNA polymerase II promoter. Includes transcription of messenger RNA (mRNA) and certain small nuclear RNAs (snRNAs).
transition between slow and fast fiber The process of conversion of slow-contracting muscle fibers to a faster character. This may involve increasing of contractile rate, fast myosin gene induction, increase in glycolytic metabolic properties, altered electrophysiology and altered innervation. This process also regulates skeletal muscle adapatation.

7 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
A7MB80 GTF2I General transcription factor II-I Bos taurus (Bovine) PR
A4IFA3 GTF2IRD2 General transcription factor II-I repeat domain-containing protein 2 Bos taurus (Bovine) PR
P78347 GTF2I General transcription factor II-I Homo sapiens (Human) PR
Q9UHL9 GTF2IRD1 General transcription factor II-I repeat domain-containing protein 1 Homo sapiens (Human) PR
Q6EKJ0 GTF2IRD2B General transcription factor II-I repeat domain-containing protein 2B Homo sapiens (Human) PR
Q86UP8 GTF2IRD2 General transcription factor II-I repeat domain-containing protein 2A Homo sapiens (Human) PR
Q9ESZ8 Gtf2i General transcription factor II-I Mus musculus (Mouse) PR
10 20 30 40 50 60
MALLGKHCDI PTNGCGSERW NSTFARKDEL INSLVSALDS MCSALSKLNT EVACVAVHNE
70 80 90 100 110 120
SVFVMGTEKG RVFLNTRKEL QSDFLRFCRG PLWNDPEAGH PKKVQRCEGG GRSLPRSSLE
130 140 150 160 170 180
QCSDVYLLQK MVEEVFDVLY SEAMGRATVV PLPYERLLRE PGLLAVQGLP EGLAFRRPAE
190 200 210 220 230 240
YDPKALMAIL EHSHRIRFKL RRPPDDGGQD TKALVEMNGI SLLPKGSRDC GLHGQASKVA
250 260 270 280 290 300
PQDLTPTATP SSMANFLYST SMPNHTIREL KQEVPTCPLT PSDLGMGWPV PEPHVPSTQD
310 320 330 340 350 360
FSDCCGQTPA GPAGPLIQNV HASKRILFSI VHDKSEKWDP FIKEMEDINT LRECVQILFN
370 380 390 400 410 420
SRYAEALGLD HMVPVPYRKI ACDPEAVEIV GIPDKIPFKR PCTYGVPKLK RILEERHSIH
430 440 450 460 470 480
FIIKRMFDER IFTGNKFTKD PMKLEPASPP EDTSTEVCRD SMLDLAGTAW SDMSSVSEDC
490 500 510 520 530 540
GPGTSGEIAM LRPIKIEPEE LDIIQVTVSD PSPTSEEMTD SLPGHLPSED SGYGMEMPAD
550 560 570 580 590 600
KGPSEEPWSE ERPAEESPGD VIRPLRKQVE MLFNTKYAKA IGTSEPVKVP YSKFLMHPEE
610 620 630 640 650 660
LFVLGLPEGI SLRRPNCFGI AKLRKILEAS NSIQFVIKRP ELLTDGVKEP VLDTQERDSW
670 680 690 700 710 720
DRLVDETPKR QGLQENYNTR LSRIDIANTL REQVQDLFNK KYGEALGIKY PVQVPYKRIK
730 740 750 760 770 780
SNPGSVIIEG LPPGIPFRKP CTFGSQNLER ILSVADKIKF TVTRPFQGLI PKPETKILTT
790 800 810 820 830 840
GHEAGKTTRP RRLQQDTWQP DEDDANRLGE KVILREQVKE LFNEKYGEAL GLNRPVLVPY
850 860 870 880 890 900
KLIRDSPDAV EVKGLPDDIP FRNPNTYDIH RLEKILKARE HVRMVIINQL QPFAEVCNDP
910 920 930 940 950 960
KVPEEDDSNK LGKKVILREQ VKELFNEKYG EALGLNRPVL VPYKLIRDSP DAVEVKGLPD
970 980 990 1000 1010 1020
DIPFRNPNTY DIHRLEKILK AREHVRMVII NQLQPFGDVC NNAKVPAKDN IPKRKRKRVS
1030 1040 1050 1060 1070 1080
EGNSVSSSSS SSSSSSNPES VASTNQISLV VKSRGSELHP NSVWPLPLPR AGPSTAPGTG
1090 1100
RHWALRGTQP TTEGQAHPLV LPTR